CJC-1295 has never been studied for weight loss. Not once. The visceral-fat data people cite for it actually comes from tesamorelin, a different GHRH analog, in a specific patient group. What CJC-1295 does to fat in a healthy adult has never been measured.
CJC-1295 is not a weight-loss drug, and the honest version of this page has to start there. It is a GHRH analog that raises the body's own growth hormone, and higher GH does nudge the body toward using fat for fuel. What it does not do is drop the number on the scale the way someone searching for weight loss expects. No trial has ever tested CJC-1295 for fat loss, weight, or body composition. What can be said about it is built from how the GH axis behaves and from data on a related drug, not from a study of CJC-1295 itself.
- No published trial has tested CJC-1295 for weight loss, fat loss, or body composition at any dose [1]
- Growth hormone promotes fat breakdown, the mechanism people are relying on, but CJC-1295's own studies measured only GH and IGF-1 [1]
- The closest real evidence is tesamorelin, a different GHRH analog, which reduced visceral fat 15.2% over 26 weeks in a specific population [2]
- GH-axis therapy targets visceral and abdominal fat over months, not rapid scale weight loss
- Any effect needs a full protocol: baseline IGF-1, a 90-day retest, and at least 6 months before judging outcomes
- CJC-1295 is not FDA-approved, and FDA has identified serious adverse events for it [3]
What CJC-1295 Actually Does to Fat
Growth hormone has a real effect on fat metabolism. It promotes lipolysis, the breakdown of stored fat, and shifts the body toward burning fat for energy. CJC-1295 raises GH and IGF-1, so in principle it engages that pathway [1]. The mechanism is genuine, and it is why the peptide gets marketed for fat loss.
The gap is between mechanism and measured outcome. CJC-1295's two human studies tracked GH and IGF-1 levels and stopped there [1]. Neither weighed anyone, scanned body fat, or followed patients long enough to see a composition change. Raising a hormone that can break down fat is not the same as a demonstrated reduction in fat, and for CJC-1295 that reduction has never been demonstrated.
The Closest Evidence Comes From a Cousin
The visceral-fat numbers attached to CJC-1295 in marketing almost always come from tesamorelin, a different GHRH analog studied for FDA approval. In a 412-patient trial over 26 weeks, tesamorelin reduced visceral adipose tissue by 15.2% versus a 5.0% increase on placebo [2]. Reviews of GHRH-analog therapy describe visceral fat as the compartment most responsive to raising GH [4].
That data is real, and it is not CJC-1295. It came from patients with HIV-associated lipodystrophy, a group with a specific fat-distribution problem, and the fat returned after treatment stopped [2]. Borrowing it to predict what CJC-1295 will do in a healthy adult is an extrapolation across two different molecules and two different populations. It suggests the class can move visceral fat. It proves nothing about a number on a scale.
Visceral Fat Is Not the Same as Weight
This is the expectation gap that sends people away disappointed. The fat the GH axis acts on is visceral and abdominal fat, the deep fat around the organs [4]. Reducing it improves waist measurement and metabolic markers, and it can change how clothes fit. It does not necessarily move body weight much, because it is a targeted redistribution rather than a large caloric deficit.
Someone expecting the fast, several-pound-a-week drop of a dedicated weight-loss medication will not get it here. GH-axis changes accrue over months, not weeks, and they show up in body composition and waistline before they show up on the scale, if they show up on the scale at all.
What CJC-1295 Will Not Do
It is not a substitute for the two things that actually drive weight loss: a sustained caloric deficit and, for many people, a GLP-1 medication with trial evidence behind it for exactly that purpose. CJC-1295 has no such evidence, and pairing a peptide that raises GH with a poor diet and no deficit produces very little.
It also is not fast, and it is not a standalone. CJC-1295 is almost always stacked with ipamorelin, and any real GH-axis protocol runs for a 6-month minimum before outcomes can be judged honestly. A vendor promising rapid weight loss from CJC-1295 is selling an outcome no study supports.
If You Pursue It, Do It as GH-Axis Therapy
The reason to consider CJC-1295 is not scale weight. It is a modest, gradual shift in body composition as part of a monitored GH-axis protocol, with realistic expectations set from the start. That means treating it as therapy, not as a fat-loss shortcut.
The discipline is the same as for any peptide on this axis. A baseline IGF-1 is drawn before the first injection, and IGF-1 is retested at about 90 days to confirm the dose is doing something without pushing the level above the age-adjusted range [1]. FDA has identified serious adverse events for CJC-1295, and it is prohibited in sport at all times [3][5], both of which belong in the decision.
The Honest Verdict
CJC-1295 is not a weight-loss drug, and no trial has ever presented it as one. It raises GH through a real fat-metabolism pathway, and the related GHRH analog tesamorelin can reduce visceral fat in the population it was studied in [2]. Between that mechanism and any promise on a sales page sits a large gap of missing evidence.
If your goal is to lose meaningful weight, CJC-1295 is the wrong tool, and the honest answer is to look at a caloric deficit and a medication proven for weight loss. If your goal is a gradual improvement in body composition as part of a monitored GH-axis protocol, then it belongs in a conversation with a prescriber who starts from a baseline IGF-1. Anyone selling it as a shortcut to the scale is selling something the data does not contain.
CJC-1295 has no weight-loss evidence, so the only honest use is a monitored GH-axis protocol with realistic expectations and a starting number to measure against. SystemLabs tests IGF-1 before prescribing and formulates CJC-1295 on clinical indication, so a body-composition goal is tracked against your labs rather than a promise on a checkout page.
Frequently Asked Questions
Does CJC-1295 cause weight loss?
Not in the way people expect. CJC-1295 raises growth hormone, which promotes fat breakdown, but no trial has ever tested it for weight loss or measured fat change on it [1]. GH-axis therapy acts on visceral and abdominal fat over months and does not reliably move scale weight. It is not a weight-loss drug.
How much weight can you lose on CJC-1295?
There is no evidence-based number, because CJC-1295 has never been studied for weight or fat loss [1]. The visceral-fat figures cited for it, such as a 15.2% reduction over 26 weeks, come from tesamorelin in patients with HIV-associated lipodystrophy, not from CJC-1295 in healthy adults [2]. Any specific weight-loss number for CJC-1295 is invented.
Is CJC-1295 or a GLP-1 medication better for weight loss?
For weight loss specifically, a GLP-1 medication has trial evidence for that exact purpose and CJC-1295 has none [1]. CJC-1295 works on body composition through the GH axis, mainly visceral fat, over months. The two are not interchangeable, and CJC-1295 should not be chosen as a weight-loss drug when the goal is losing weight.
How long does CJC-1295 take to affect body fat?
GH-axis changes are gradual. A real protocol runs for a 6-month minimum before body-composition outcomes can be judged, with IGF-1 retested at about 90 days to confirm the dose is working [1]. Anyone expecting a visible change in a few weeks has the wrong timeframe for how this axis works.
Is CJC-1295 safe for weight loss?
CJC-1295 is not approved for weight loss or anything else, and FDA has identified serious adverse events for it, including increased heart rate and systemic vasodilatory reaction [3]. It is dispensed only as a compounded preparation and is prohibited in sport at all times [5]. Used at all, it requires a prescribing physician and a baseline IGF-1, not a self-directed fat-loss experiment.
References
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults Journal of Clinical Endocrinology & Metabolism, 2006. PMID: 16352683. https://pubmed.ncbi.nlm.nih.gov/16352683/
- Metabolic effects of a growth hormone-releasing factor in patients with HIV New England Journal of Medicine, 2007. PMID: 18057338. https://pubmed.ncbi.nlm.nih.gov/18057338/
- Certain bulk drug substances for use in compounding that may present significant safety risks FDA.gov, Human Drug Compounding, 2026. Content current as of 04/22/2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- Effects of growth hormone-releasing hormone on visceral fat, metabolic, and cardiovascular indices in human studies Growth Hormone & IGF Research, 2015. PMID: 25555516. https://pubmed.ncbi.nlm.nih.gov/25555516/
- The 2026 Prohibited List: International Standard, section S2.2.4 growth hormone releasing factors World Anti-Doping Agency, 2026. WADA 2026 Prohibited List. https://www.wada-ama.org/en/resources/2026-prohibited-list
